drug
EPI-321
Phase 2updated 6mo agoby Epicrispr Biotechnologies Inc
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying EPI-321
News(4)
- Epicrispr builds case for FSHD treatment with updated data for EPI-321Epicrispr Biotechnologies continued to show encouraging findings from testing of its epigenetic editing treatment for the genetic muscle disease facioscapulohumeral muscular dystrophy. Twelve peopl…endpoints · 1mo ago
- Epicrispr, Infinimmune snag combined $165M in VC cashEpicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.biospace · 3mo ago
- Epicrispr lands $90M to advance epigenetic editing drug for rare muscle diseaseThe startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.biopharma_dive · 3mo ago
- Epicrispr raises $90M to rewrite treatment of rare muscle diseaseEpicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…fiercebiotech · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that